Patrick Hwu, President and CEO at Moffitt Cancer Center, shared on X:
“What if we could help the immune system fight cancer by targeting the cells that are holding it back?
New research published in Nature Communications reveals how a protein called SATB1 helps regulatory T cells (immune cells that normally prevent harmful inflammation) take on tumor-promoting roles within the tumor microenvironment.
In the study, researchers found that removing SATB1 specifically from regulatory T cells weakened their ability to suppress antitumor immune responses, allowing the immune system to mount a stronger attack against cancer. Importantly, the findings suggest this approach may preserve regulatory T cells’ ability to control harmful inflammation elsewhere in the body.
This discovery offers new insight into how scientists might selectively disrupt cancer’s immune defenses while preserving the immune system’s normal protective functions. This is a promising direction for developing more precise immunotherapies!”
Title: The chromatin-organizer Satb1 modulates regulatory T cell activity within the tumor microenvironment
Authors: Ephraim A. Ansa-Addo, Parviz Azimnasab-Sorkhabi, Huai-Cheng Huang, Brian P. Riesenberg, Musab Bouhajra, Partha Biswas, Mohammadreza Sepand, Afryea Henderson, Maria Velegraki, Payton Weltge, Donna Bucci, Mark P. Rubinstein, Dongjun Chung, Eugene M. Oltz, Scott I. Abrams, Zihai Li
Read the Full Article on Nature Communications
Mario Balsa, Medical Oncologist at Hospital Clínic de Barcelona, shared this post, adding:
“The dream in immuno-oncology: disarm the Tregs in the tumor without unleashing them everywhere else.
SATB1 may offer exactly that kind of precision! Still preclinical, but a fascinating concept!”
You can also read: The Tumor Microenvironment and Immune Escape: Mechanisms and Therapeutic Implications
